Back to search

Peptide record

TPDB09150

Antibacterial Anticancer Antifungal Hemolysis Toxicity standard
19 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB09150
Antibacterial Anticancer Antifungal Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 DRAMP Peptipedia dbACP Antifungipept CAFPdb dbAMP HemoPI Hemolytic2 PD_Hemolysis
standard
No
A 19-aa standard-residue multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, DRAMP, Peptipedia, and other sources, with an available 3D structural model.
Sequence
GFKDLLKGAAKALVKAVLF
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C96H161N23O22
RNCEQHIMPSTWY
ALK
1989.48
10.55
4
1
12
+3
-0.63
0.868
133.68
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
0
0.00
0
Residue Composition
number
4
A
0
R
0
N
1
D
0
C
0
E
0
Q
2
G
0
H
0
I
4
L
4
K
0
M
2
F
0
P
0
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 4 R: 0 N: 0 D: 1 C: 0 E: 0 Q: 0 G: 2 H: 0 I: 0 L: 4 K: 4 M: 0 F: 2 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
19 reviewed residue count
C96H161N23O22 sequence-only estimate (linear, free termini)
1989.48 sequence-only estimate (linear, free termini)
10.55 sequence-only estimate (linear, free termini)
+3 sequence-only estimate (linear, free termini)
-0.63 sequence-only estimate (linear, free termini)
0.868 sequence-only estimate (linear, free termini)
Evidence Records 5 records
Evidence 1 Activity

Activity

LC50
Hemolysis
22 µM
[Ref.18554256]Hemolysis against human erythrocytes (LC50=22 µM).

Target

human erythrocytes

Source & Reference

Hemolytik PD_Hemolysis
DRAMP4
Chem Biol Drug Des. 2008 Jul 72(1):58-64.

Other

Source Activity Label Source Definition
Hemolysis
Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 2 Activity

Activity

50% Hemolysis
Toxicity
22 µM
Hemolytic Cytotoxic
50% Hemolysis | 22 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of potent, non-toxic antimicrobial agents based upon the naturally occurring frog skin peptides, ascaphin-8 and peptide XT-7. | Chem Biol Drug Des | 2008
Evidence 3 Activity

Activity

50% Cell death
Toxicity
5 µM
Cytotoxic
50% Cell death | 5 | µM | target cell: Mouse fibroblasts L929

Target

Mouse fibroblasts L929

Source & Reference

NA
DBAASP
Design of potent, non-toxic antimicrobial agents based upon the naturally occurring frog skin peptides, ascaphin-8 and peptide XT-7. | Chem Biol Drug Des | 2008
Evidence 4 Activity

Activity

LC50
Toxicity
22 µM
Hemolytic Cytotoxic
Hemolytic_activity: [Ref.18554256]Hemolysis against human erythrocytes (LC50=22 µM). | Cytotoxicity: [Ref.18554256]Cytotoxicity:Mouse fibroblasts L929 (LC50=5 µM).

Target

erythrocytes

Source & Reference

NA
DRAMP
Chem Biol Drug Des. 2008 Jul 72(1):58-64.
Evidence 5 Hemolysis

Activity

22 µM
LC50
[Ref.18554256]Hemolysis against human erythrocytes (LC50=22 µM).
Hemolysis

Target

human erythrocytes

Source & Reference

HemoPI PD_Hemolysis
Chem Biol Drug Des. 2008 Jul 72(1):58-64.
DRAMP4
PD_Hemolysis